BioSig Technologies (BSGM +13.7%) subsidiary ViralClear Pharmaceuticals has filed an application with
the FDA seeking sign-off for a Phase 2 clinical trial evaluating
broad-spectrum antiviral merimepodib in 20 patients with advanced
COVID-19 infection.
Yesterday, the company announced positive results from lab studies comparing merimepodib to Gilead’s remdesivir.
https://seekingalpha.com/news/3564195-biosig-files-ind-for-merimepodib-study-in-covidminus-19-shares-up-14
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.